{"nctId":"NCT01652729","briefTitle":"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2013-02"},"conditions":["Diabetes Type 2"],"count":365,"armGroups":[{"label":"Exenatide once weekly suspension","type":"EXPERIMENTAL","interventionNames":["Drug: Exenatide once weekly suspension"]},{"label":"Sitagliptin 100mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sitagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Exenatide once weekly suspension","otherNames":[]},{"name":"Sitagliptin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years old\n* Diagnosed with type 2 diabetes mellitus\n* HbA1c of 7.1% to 11.0%, inclusive, at screening\n* Has stable body weight, i.e., not varying by \\>3% for at least 3 months prior to screening\n* Fasting plasma glucose concentration \\<280 mg/dL (15.5 mmol/L) at screening\n* Body mass index of \\<45 kg/m2 at screening\n* Has been treated with a stable regimen of ≥1500 mg/day metformin for a minimum of 2 months prior to Visit 1 (Screening)\n\nExclusion Criteria:\n\n* History of pancreatitis or triglycerides \\>=500 mg/dL\n* Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either\n* History of renal transplantation, or is currently receiving renal dialysis, or has an estimated creatinine clearance \\<50 mL/min\n* Active cardiovascular disease\n* Presence or history of severe congestive heart failure\n* Central nervous system disease, including epilepsy\n* Liver disease\n* History of severe gastrointestinal diseases\n* Clinically significant malignant disease\n* Repeated severe hypoglycemia within the last 6 months\n* Any exposure to exenatide (BYETTA® or BYDUREON™) or any GLP-1 analog\n* Any DPP-4 inhibitor within 3 months prior screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","description":"Absolute change in HbA1c from baseline (Day 1, Visit 3) to Week 28/Study Termination (Visit 11). Hypothesis testing on the primary endpoint followed a serial gated procedure with all tests carried out at a 2-sided significance level of 0.05 to protect the family-wise error rate. These tests were conducted sequentially, and are presented in the statistical analysis section below in the order in which they were performed; each test was the gatekeeper of later tests.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.13","spread":"0.1093"},{"groupId":"OG001","value":"-0.75","spread":"0.1324"},{"groupId":"OG002","value":"-0.40","spread":"0.1945"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving HbA1c <7% at Week 28","description":"Percentage of subjects achieving HbA1c target values of \\< 7.0% at Week 28/Study Termination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.7","spread":null},{"groupId":"OG001","value":"98.4","spread":null},{"groupId":"OG002","value":"96.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"32.0","spread":null},{"groupId":"OG002","value":"24.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null},{"groupId":"OG001","value":"68.0","spread":null},{"groupId":"OG002","value":"75.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28","description":"The change in fasting plasma glucose concentrations from baseline (Day 1) to Week 28/Study Termination.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.3","spread":"3.864"},{"groupId":"OG001","value":"-11.3","spread":"4.617"},{"groupId":"OG002","value":"9.6","spread":"7.097"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (kg) From Baseline to Week 28","description":"The change in body weight (kg) from baseline (Day 1) to Week 28/Study Termination.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"0.2592"},{"groupId":"OG001","value":"-1.19","spread":"0.3134"},{"groupId":"OG002","value":"0.15","spread":"0.4767"}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16 (Visit 8)","description":"The change in 2-hour postprandial plasma glucose from baseline (Day 1) to Visit 8 (Week 16) was analyzed using a general linear model including treatment, and baseline HbA1c stratum (\\< 9% or ≥ 9%) as fixed factors, and the baseline 2-hour postprandial plasma glucose concentrations as a covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.57","spread":"10.48"},{"groupId":"OG001","value":"-23.61","spread":"13.04"},{"groupId":"OG002","value":"-38.68","spread":"16.98"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":181},"commonTop":["Nausea","Injection Site Nodule","Nasopharyngitis"]}}}